An observational study in New Tumor Diagnostics From Human Plasma Samples, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to participants aged 50 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by Assiut University · Observational
Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.
Cell free circulating free nucleic acids is new substrates for laboratory diagnostics in a number of medical areas including oncology, transfusion medicine, gynecology/obstetrics, inflammatory and autoimmune diseases etc.There are various qualities of cell free nucleic acids. In oncology, it has been shown that the early detection of cell free nucleic acids originating from the tumour preceeds the diagnostic detection of clinical relapse as done by imaging techniques or clinical symptoms by 6-8- months.
Exosomes are small, lipid bilayer membrane vesicles (30-100 nm) that are released from all cell types into the extracellular space. These tiny membrane vesicles transmit EV-mediated signals by proteins, lipids, nucleic acids and sugars, and the unique molecular pattern of this package direct the type of extracellular signal to be transmitted to target cells. Interest in exosomes range from their mode of action and various functions in the body to more practical applications such as development of biomarkers based on analysis of their RNA and protein content and their use in clinical diagnostics. It was proposed that micro RNAs are transferred through exosomes to recipient cells and can there mediate repression of their mRNA targets.
The use of highly expensive targeted therapies (e.g. tyrosine kinase inhibitors or PARP inhibitors) may become obsolete during therapy due to changes in the mutational molecular profile of the malignant tumour. Indeed, if early detection of cell free nucleic acids suggest therapy failure, new stratification of the patient and changed therapy modalities may be possible in the future, thus helping to prolong overall survival of tumour patients.
Aims of the Research:
Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Study group: 15 Patients control Group: 10 Persons
Exclusion Criteria:
15 patients of with Melanoma, Age between 40 and 90 years. -Withdrawal of Blood sample, Isolation of Exosomes: 1. Bradford protein assay And Qubit protein assay. 2. Bioanalyzer. 3. Real time PCR.
10 Persons without Melanoma, age \> 40 years -Withdrawal of Blood sample, Isolation of Exosomes: 1. Bradford protein assay And Qubit protein assay. 2. Bioanalyzer. 3. Real time PCR.
Isolation of Exosomes as a stable source of nucleic acid as an early Detection Method to diagnose Melanoma.
Real time PCR for detecting the presence of Melanoma relevant nucleic acids isolated of Exososmes.
Time frame: one year
This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University